Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-714-0555
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees82
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions
What is Constellation Pharmaceuticals' stock symbol?
Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."
How were Constellation Pharmaceuticals' earnings last quarter?
When is Constellation Pharmaceuticals' next earnings date?
What price target have analysts set for CNST?
4 equities research analysts have issued 12-month price targets for Constellation Pharmaceuticals' shares. Their forecasts range from $17.00 to $20.00. On average, they anticipate Constellation Pharmaceuticals' share price to reach $18.25 in the next year. This suggests a possible upside of 43.4% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.
What is the consensus analysts' recommendation for Constellation Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.
Has Constellation Pharmaceuticals been receiving favorable news coverage?
Media coverage about CNST stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Constellation Pharmaceuticals earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Constellation Pharmaceuticals.
Are investors shorting Constellation Pharmaceuticals?
Constellation Pharmaceuticals saw a decrease in short interest in September. As of September 30th, there was short interest totalling 723,200 shares, a decrease of 34.3% from the August 30th total of 1,100,000 shares. Based on an average trading volume of 63,700 shares, the short-interest ratio is currently 11.4 days. Approximately 6.5% of the company's shares are short sold. View Constellation Pharmaceuticals' Current Options Chain.
Who are some of Constellation Pharmaceuticals' key competitors?
Some companies that are related to Constellation Pharmaceuticals include Radius Health (RDUS), BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA), Turning Point Therapeutics (TPTX), ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Zymeworks (ZYME), Endo International (ENDP), Innoviva (INVA), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Theravance Biopharma (TBPH), AnaptysBio (ANAB), Amphastar Pharmaceuticals (AMPH) and Epizyme (EPZM).
What other stocks do shareholders of Constellation Pharmaceuticals own?
Who are Constellation Pharmaceuticals' key executives?
Constellation Pharmaceuticals' management team includes the folowing people:
- Mr. Jigar Raythatha, Pres, CEO & Director
- Ms. Emma Reeve, Sr. VP, CFO Treasurer & Sec. (Age 58)
- Dr. Adrian M. Senderowicz, Sr. VP & Chief Medical Officer (Age 55)
- Dr. Danny Reinberg Ph.D., Co-Founder
- Dr. Yang Shi Ph.D., Co-Founder
When did Constellation Pharmaceuticals IPO?
(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.
How do I buy shares of Constellation Pharmaceuticals?
Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Constellation Pharmaceuticals' stock price today?
One share of CNST stock can currently be purchased for approximately $12.73.
How big of a company is Constellation Pharmaceuticals?
Constellation Pharmaceuticals has a market capitalization of $328.73 million. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.
What is Constellation Pharmaceuticals' official website?
How can I contact Constellation Pharmaceuticals?
Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]
MarketBeat Community Rating for Constellation Pharmaceuticals (NASDAQ CNST)
MarketBeat's community ratings are surveys of what our community members think about Constellation Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNST will underperform the S&P 500 over the long term. You may vote once every thirty days.
